Review Article

Plasma Cell Neoplasms with Spreading in the Blood and Tissues: Extramedullary Myeloma Disease, a Rare Aggressive Form of Multiple Myeloma (First of Two Parts)

Ugo Testa[1] and Giuseppe Leone[2].

[1] Istituto Superiore di Sanità
[2] Università Cattolica del Sacro Cuore

Abstract. Multiple myeloma is a disease related to the proliferation of malignant plasma cells; in most patients, the disease is confined to the level of bone marrow. However, in a minority of patients, the malignant plasma cells are also localized outside the bone marrow, either at the level of peripheral blood (plasma cell leukemia) or at the level of soft tissues (extramedullary multiple myeloma). These two rare forms of aggressive MM (ultrahigh-risk (uHR) MM as MM leading to death within 24-36 months) are both associated with some molecular features and with a limited response to current treatments.

Correspondence to: Giuseppe Leone. Università Cattolica del Sacro Cuore. E-mail: giuseppe.leone@unicatt.it

Introduction. MM is characterized by the outgrowth of malignant plasma cells in the bone marrow; however, variable numbers of circulating tumor plasma cells (CTPCs) are observed in these patients and are present in a particular way in two forms of ultrahigh risk, Extramedullary Myeloma and Plasma Cell Leukemia (**Table 1**).[1]

Table 1

Plasma cell neoplasms with spreading in the blood and tissues	Definition
Paraskeletal plasmacytoma	A form of multiple myeloma characterized by the presence of soft-tissue plasmacytomas that occur due to direct growth from skeletal tumors following cortical bone disruption
Extramedullary disease	An aggressive form of multiple myeloma characterized by the presence of soft-tissue plasmacytomas that result from hematogenous spread
Plasma cell leukemia	A rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells; diagnosis is based upon the percentage ($\geq$20%) and absolute number ($\geq$2 × 10^9/L) of plasma cells in peripheral blood

Importance of Circulating Tumor Plasma Cells (CTPCs). At diagnosis, CTPSs are routinely quantified in peripheral blood by morphology but can be evaluated with much more sensitivity and precision by flow cytometry. Studies carried out using low-sensitivity methods of evaluation of CTPSs have shown a PB involvement by CTPCs of 19-37% in MGUS, 50-75% in Multiple Myeloma (MM), and 100% in plasma cell leukemia (PCL).[2] Using flow cytometry for CTPC detection, 59% of MGUS, 100% of Smoldering MM, and

100% of MM have detectable CTPCs.[2] This study also showed that a higher number of CTPCs in PB was associated with higher levels of bone marrow infiltration and more adverse prognostic features in MM and with shorter time to progression to MM in SMD patients.[2]

The presence and particularly the number of CTPCs was considered a possible negative prognostic factor for MM patients; however, no association was detected between CTPC levels and response to induction treatment.[2] The presence of more than 20% clonal plasma cells by differential count of the leucocytes or by counting more than 2×10^9 per liter in peripheral blood characterizes plasma cell leukemia. However, patients with lower levels of circulating plasma cells have the same adverse prognosis, which challenges the disease definition.[3] However, several recent studies have shown that CTPCs above some levels are associated with reduced PFS in MM patients,[4-11] and to define PCL, the percentage of CTPCs has been lowered. Levels of CTPCs were evaluated by next-generation flow cytometry, and detectable levels were observed in 86.8% of cases; higher levels of CTPCs (>0.1% of all PBMCs) were strongly correlated with an increased BM infiltration by myeloma cells, with ISS-3 stage disease and with the presence of high-risk cytogenetics t(4;14), t(14;16) and del(17p); furthermore, there was a correlation between higher CTPC levels and high serum creatinine levels.[4] Finally, it was observed that there is a trend for inferior PFS in patients with high CTPCs.[5] Low cutoffs, different according to the methods utilized, have been defined as optimal to stratify MM patients.[5-8]

Garcés et al., using the data from GEM2012MENOS65 and GEM2014MAIN clinical trials,[5] and Bertamini et al., using the results from the FORTE trial,[6] have explored the clinical significance of CTPCs and have defined optimal cutoffs, respectively, of 005% and 001%, to stratify MM patients eligible for transplantation. Furthermore, patients with undetectable CTPC levels had very good PFS and MRD status.[5,7] Interestingly, CTPC levels, but not the bone-marrow plasma-cell levels, affected the outcome.[6]

These results were confirmed by Kostopoulos and coworkers, who defined the level of $2x10^{-4}$ CTPC, corresponding at about 0.01%, as a reliable cutoff to distinguish high CTPC and low CTPC patients, with the high group exhibiting a significantly shortened progression-free survival (PFS) compared to the low group.[7] In a more recent report updated to 550 MM patients, the same authors have better defined the cutoff of CTPC level at 0.02% and have shown that about 10% of patients with undetectable CTPC levels have a particularly favorable prognosis with a 5-yr PFS and OS of 83% and 97%, respectively and with an achievement of MRD- negativity of 73% after 2-year of treatment.[8]

Jelinek and coworkers have assessed the levels of CTPCs by multiparameter flow cytometry in 395 patients with newly diagnosed MM not eligible for transplantation; patients with CTPCs comprised in the range between 2% and 20% represent about 4% of the whole cohort and displayed shorter PFS compared with patients with <2% CTPCs (3.1 vs 15.6 months, respectively), as well as shorter OS (14.6 vs 33.6 months, respectively).[8] Patients in the 2-20% group had a higher frequency of ISS III stage, elevated LDH levels, and higher frequency of high-risk cytogenetic abnormalities.[9] These observations were also extended to a group of MM patients eligible for transplantation, showing reduced PFS and OS in the group of patients with 2-20% CTPCs compared to those with <2% CTPCs.[9] Finally, patients with 2-20% CTPCs have comparable prognosis with respect to patients with primary PCL.[9] In conclusion, this study showed that a cutoff of CTPCs allowed defining a subgroup of ultra-high-risk MM patients.[9] All these observations strongly support the inclusion of CTPC evaluation by flow cytometry as a standard part of diagnostic workup of MM patients.[8]

The inclusion of the evaluation of CTPCs at diagnosis by flow cytometry into the standard-risk assessment may improve the identification of high-risk patients, optimizing their treatment as shown by recent studies.[10,11]

All these investigations suggest that plasma cell independence from the bone marrow microenvironment represents a major evolutionary step in disease biology, and accordingly. This characteristic is common in a different way to the two disease entities of PCL and EMD, and both PCL and EMD are included in the group of high-risk and ultrahigh-risk multiple myeloma.[1,12] The revised IMWG definition of PCL requires ≥5% circulating plasma cells (CPCs).[3,12] However, the spectrum of risk exists below this threshold. It has been recognized with sensitive flow cytometric assays, ranging from low risk with no detectable CPCs to HR with many CPCs.[13]

CPCs are also found more frequently detected by flow cytometry in extramedullary plasmacytoma (EMP) patients than in the other forms of myeloma and worsen their prognosis.[13-15]

Extramedullary Multiple Myeloma. Extramedullary myeloma disease (EMD) is a rare manifestation of multiple myeloma (MM) characterized by the proliferation of malignant plasma cells outside the bone marrow. It is traditionally considered as a group of patients associated with poor prognosis. However, functional whole-body techniques should ideally be used to detect EMD. A consensus statement by the International Myeloma Working Group (IMWG) specifically recommends 18F-FDG PET/CT for this purpose; magnetic resonance (MRI) is the best imaging approach for spinal and central nervous system (CNS)

involvement.[15] The condition of EMD can be diagnosed at the time of primary diagnosis and is defined as primary EMD (pEMD) (3-5%) or at the time of disease relapse and is defined as secondary EMD (sEMD) (6-20%).[14,15]

Here, we discuss the diagnosis, molecular abnormalities, and prognostic criteria of extramedullary multiple myeloma (EMM), also called myeloma extramedullary disease (EMD), in comparison with plasma cell myeloma (PCL).

In one hypothetical model of EMD pathogenesis, metastatic myeloma cells initially exit the bone marrow, translocate into the blood as clonal circulating plasma cells (CPCs), and finally settle in peripheral tissues and form an extramedullary plasmacytoma (EMP).[1,15] The interaction between myeloma cells and the BM microenvironment activates signaling cascades and mediates chemotaxis and adhesion of myeloma cells to BM. The mechanisms of extramedullary spread in MM are not well understood. Some possible mechanisms are: (i) decreased expression of adhesion molecules, such as CD44, or loss of CD56, which could result in disease dissemination by impairing the adhesion of malignant plasma cells to the bone marrow endothelium, (ii) low expression of chemokine receptors or downregulation of CXCR4 and its ligand CXCL12 (previously termed SDF-1a), which is linked to the bone marrow homing of myeloma cells, (iii) increased angiogenesis or (iv) bone marrow hypoxia resulting in the egress of bone marrow plasma cells. Therefore, it is reasonable to say that the overexpression of CD56 on myeloma cells favors their adherence capacity within the BM while its downregulation favors the migration of myeloma cells in the PB Tumor dissemination occurs due to (i) low expression of chemokine receptors and adhesion molecules,[1] (ii) under expression of membrane-embedded CS81/CD 82 tetraspanins and overexpression of tumor promoter heparanase enzyme, (iii) upregulation of CXCR4 by various growth factors and hypoxic conditions in tumor microenvironment and acquisition of EM phenotype regulated by CXCR4.[15-17] Furthermore, the loss of E-cadherin expression and the induction of N-cadherin are known as hallmarks of the epithelial-to-mesenchymal transition, an essential initial step in the process of metastasis in solid tumors. Negative E-cadherin expression on BM myeloma cell membranes was significantly associated with the spreading of CMTC and the presence of soft tissue masses arising from bone lesions and breaking through the cortical bone, referred to as extramedullary disease (EMD) (**Table 2**).[18]

Bladé and coworkers have distinguished two types of

Table 2. Mechanisms of extramedullary spread in MM.

Factors resulting in disease dissemination by impairing the adhesion of malignant plasma cells to the bone marrow endothelium:
(i) decreased expression of adhesion molecules, such as CD44, or loss of CD56, Negative E-cadherin expression on BM myeloma cell
Low expression of factors favoring the homing in bone marrow
(ii) low expression of chemokine receptors or downregulation of CXCR4 and its ligand CXCL12 (previously termed SDF-1a)
(iii) increased angiogenesis
(iv) bone marrow hypoxia resulting in regression of bone marrow plasma cells

EMD, one with location of soft tissue masses in extraosseous sites resulting from hematogenous spreading and the other with extension of malignant plasma cells to contiguous soft tissues through disruption of cortical: (i) the first is defined as extramedullary disease (EM-E) and (ii) the second as paraskeletal plasmacytoma (EM-B), about 80% of the EMD are paraskeletal.[15] At diagnosis, EM-E is typically found in skin and soft tissues; at relapse, typical sites are represented by the liver, kidneys, lymph nodes, central nervous system, breast, pleura, and pericardium.[15-17] In a recent review of the literature, Bansal et al. proposed a classification of EMD into three subgroups: (i) bone-associated EMD with MM with soft tissue mass arising from bone lesions and growing contiguously; (ii) bone-independent EMD with MM, with isolated extra-osseous plasma cell tumors not contiguous with bone lesions; (iii) organ-infiltrating EMD with CNS myeloma, diffuse liver involvement or other extra-osseous tissues.[17]

EMD may occur alongside MM diagnosis in the later stages of disease development or in relapse. The EMD is usually observed with concomitant involvement of bone marrow and extramedullary sites, but in some patients, there is involvement of multiple extramedullary sites without bone marrow involvement. EMD, particularly in the form of EM-E, is considered a high-risk factor associated with reduced OS compared to MM without EMD.[1,11,15]

The reported incidence of EMD varies considerably in different studies, and this is due also to the differences in the diagnostic approach; thus, in newly diagnosed MM, the reported incidence varies from 0.5% to 4.8%, and in relapsed MM from 3.4% to 14%.[15] However, at least another 20% of patients develop EMD during their disease course.[15] The paraskeletal forms bone-associated (EM-B) are at diagnosis 2-4 times more frequent than the forms bone independent, Their prognosis tends to be like that of myeloma without extramedullary disease; on the contrary, the subgroup with hematogenous spreading and localizing the soft tissue has a very bad prognosis.[15,17] The presence of Circulating Tumor Plasma Cells worsens the prognosis.[11,13]

Studies Defining Cytogenetic and Molecular Abnormalities in Emm (EMD). Primary genetic events involved in MM include immunoglobulin heavy chain gene translocations and hyperdiploidy. In general, patients with translocations t(4;14), t(14;16), and t(14;20) are considered high-risk, whereas patients with t(11;14) are considered standard-risk and have a better prognosis. As MM progresses, secondary genetic aberrations develop, including mutations and copy number abnormalities, del(13q), del(17p), del(1p), and gain of 1q.[19] A few studies have defined the cytogenetics[20-28] and molecular[29-34] abnormalities observed in EMD, many of them are high risk, such as t(4;14), del(17p13), del(13) and chromosome 1 aberrations and p53 mutations (**Table 3**).

Table 3. Summary of the most relevant genomic studies carried out in EMD (EMM).

Author, Year, Reference	Methodology	Patients	Significant Results
Varga, 2016, 20	FISH	34 EMM from 117 resist. to Bortezomid	IgH translocation, del(13/13q) and del(17) not predictive
Rasche, 2012, 21	FISH	19 MM → EMM	>13q deletion (58%) > t(4;14) and 17p deletion
Billecke, 2013, 22	FISH	19 EM-E 11 EM-B MM Standard	del(17p13)= 32% del(17p13)= 27% del(17p13)= 8-16%
Besse, 20013, 23	FISH	22, BM 18, extramedullary 12 BM+Extramed.	>t(4;14) in extramed. Cells. > hyperdiploidy BM
Qu, 2015, 24	FISH	29EMM 134 MM	>del(17p13)=29% >amp(1q21) =57% del(17p13)=13% ; amp(1q21)=32%
Kriegova, 2021, 25	Whole-genome optical mapping	7 EMM	Loss 17p 13. Chrom 1 abnor. more del. and fewer intrachrom. transloc
Xia 2022, 26	FISH	30 EMM BM 30 EMM extramed	P53= 3.3% and IgH translocation=30 P53 del = 33% IgH translocations= 43%
Song 2024, 27	FISH	non-EMD, 339 pEMD-B, 48 pEMD-S 33 sEMDS 19	RB1 del 60% vs 20% MYC transl 44,4% vs 12.5% OS 32 vs 60
Gao, 2024,28	FISH	96 EMM patients at diagnosis	23% 1q21+ was strongly associated with t(14;16) and t(14;20, poor outcome
Deng. 2015, 29	FISH	834 pts, EMM 4.8%	. p53 deletion in EMM, 34.5% vs 11.9%,
Andrulis, 2013, 30	Sanger sequencing	MM 251 EMM 7	BRAFV600E mutations at onset 4/7 BRAF-mutated patients (57%) EMM Vs. 43/251 MM
De Haart, 20016, 31	FISH; NGS	14 EMM	3/12 1q+; RAS mutations in BM 6 / 9 patients (67%) and in EM 7/11 (64%).
Liu, 2020, 32	FISH; NGS	10 EMM	Deletion of 1p 2/5 gain of 1q 4/5 cases 6/6 mutations of genes in RAS pathways
Nakamoto-Matsubara, 2021, 33	SNaPshot (molecular) testing. FISH	MM 443 EMM 96	NRAS+KRAS+BRAF 29/30 EMM examined. RAS worse prognosis and displaying + Chrom 1 abn.+TP53: - Hyperplodiploidy
Saladarriaga, 2023, 34	whole exome sequ. (WES), and RNA sequencing (RNAseq)	EMM 130 vs MM 778	Del 17p 11.9 vs 10.0, p= 0.62 Gain 43.7 % vs 36.9, p= 0.16 MYC 27.8% vs 15.5,p= 0.001 Del 18q 23.0% vs 14.1, p= 0.015 TP53+ mut. 9.6 vs 4.4) p= 0.020 CNA + Mut 7.3% vs 2.9% p= 0.016
Jelinek, 2024, 35	FISH; RNA and WES	14 EMM	1q21 gain/amp 85%, 1q21 gain/amp 57% ; del(17p) and TP53 43%; t(4;14) 14% Members of MAPK pathway mutated in all EMM sample: KRAS 71%, NRAS 14%, BRAS 7%; TP53 36%. 80% of gene mutation transcribed in RNA 1q21 gain/amp +mutated KRAS= H R.

High-risk cytogenetic abnormalities were generally more frequent in EMD patients than in patients with MM. High risk translocations like t(4;14), t(14;16), or t(14;20) were considered primary genetic events, and C-MYC translocation and also IgH translocations were found more frequently in myeloma patients with EMM. The same was true for some secondary genetic aberrations. Deletion of 17p was found more frequently (>30%) in patients with EMM than in those without EMM,[20,21,22,24,36] and its frequency was higher in EM-E

subjects than in EM-B.[23] Similarly, more frequent in EMM was the 13q deletion (**Table 3**).[20,21,23,25,34]

Gains of 1q and 1p deletion were also more frequent in patients with EMM than without, particularly in relapse.[24,28,34,36] The deleted or mutated P53 gene was more frequent in bone marrow cells of myeloma patients with EMM.[26,29,35,36] Hyperploidity was less frequent in EMM,[34] and no MM patient with t(11;14) developed EMM.[20] The presence of high risk cytogenetic aberration, like t(4;14) could be predictive of the evolution of MM in EMM.

The mutations characterizing the EMM belong mostly to the RAS family,[30-36] with a prevalence of BRAF genes.[30,34,36] Although the presence of high-risk cytogenetic aberrations is elevated, it does not completely justify the bad prognosis of MM with EM-E, which is itself an independent risk factor that should be included among the risk factors.[10,11] It is noteworthy that although there is no difference in the presence of high risk cytogenetic aberrations, there is a difference in survival between the two forms of EMM, EM-E, and EM-B.[22,23]

Besse et al. explored cytogenetic abnormalities of 31 EM patients by FISH analysis. Of these, 16 patients had soft tissue-related EM, and 15 had bone-related EM. In these patients, 25 samples of bone marrow plasma cells (BMPCs) and 18 samples of tumor plasma cells were examined with FISH for del(13q14), 14q32 disruptions, Del(17)(p13), (4;14)(p16;q32), (14;16)(q32;q23), Gain(1)(q21), Hyperdiploidy; there was no significant difference in the frequency of these abnormalities, apart from a significant major frequency of hyperdiploidy in BMTPCs and a not significant increase of t(14;16) in extramedullary plasma cell; however, in the 12 EMM patients where TPCs were examined in paired BM and EMD samples, also these differences were not significant.

The frequency of genomic events was increased in patients at the time of EMD diagnosis compared to MM samples obtained prior to EMD evolution.[23]

Kriegova et al. have used whole-genome optical mapping to explore the genomic architecture of EMM; this technique shows a significant advantage in detecting small and large structural rearrangements as well as complex rearrangements across the whole genome that are undetectable using traditional methods.[25] Large intrachromosomal rearrangements within chromosome 1 were detected in all EMM samples. These rearrangements predominantly involve deletions without or with inversions, englobe hundreds of genes, and determine copy number alterations encompassing large regions of chromosome 1. Compared to MM, EMM displayed more deletions and fewer intrachromosomal translocations; finally, 2/7 of the EMM analyzed displayed copy number loss in the 17p 13 region.[25]

Song et al. have analyzed a total of 439 patients with NDMM, divided into those without EMD (non-EMD, n = 339), those with EMD with primary para-osseous plasmacytoma (pEMD-B, n = 48), those with primary EMD with soft-tissue involvement (pEMD-S, n = 33), and those with secondary EMD (sEMD, n = 19).[27] The incidence of EMD was 18.5% (81/439) at diagnosis and 22.8% (100/439) throughout the disease course. Comparison of FISH results showed a higher proportion of RB1 deletion (n = 20; 60.0% vs. 20.0%, p = .013) and MYC translocation (n = 12; 44.4% vs. 12.5%, p = .041) in the extramedullary tissues than in the paired bone marrow samples. At diagnosis, the percentage of MYC translocations in the sEMD group was notably higher than that in the non-EMD group (55.6% vs. 15.5%, p = .012). The median overall survival (OS) of patients with pEMD-S (32 months) and sEMD (17 months) was significantly shorter (both p = .001) than that of non-EMD patients (60 months).[27]

The mutations of the genes of the RAS family have been described by a few authors.[30-34, 37] These mutations seem to be more frequent in the extramedullary tissues and secondary EMM after more relapses[33,34] and can coexist with other mutations, like TP53[33] and with chromosome 1 abnormalities;[33,34] it is noteworthy that the prognosis of patients with RAS family mutations is worse in patients with EMM than in MM, particularly when associated to chromosome 1 abnormalities.[33,34]

Furthermore, Jelinek and coworkers, in the transcriptomic analysis of EMM cells, suggest a higher proliferation and decreased homing to bone marrow (downregulation of CXCR4) compared to MM cells.[34] Importantly, EMM samples displayed reduced expression of immunotherapeutic targets, such as CD38, SLAMF7, and GPRC5D.[34]

Significantly, mice with deletion of the X-linked Utx associated with the activating Braf^{V600E} mutation developed MM-like neoplasms, expanding its clonal plasma cells both in the bone marrow and extramedullary organs.[35]

Circulating tumor DNA (ctDNA) profiling could be adopted as an alternative to MM bone marrow aspirates for the evaluation of genetic abnormalities.[37] The analysis of 8 EMM patients using ctDNA showed that 100% of these patients exhibited RAS pathway mutations: 5/8 *KRAS*, 2/8 *NRAS*, and 1/8 *BRAF* mutations (36). Interestingly, *BRAFV600E* mutation, in cooperation with UTX gene inactivation in germline center B cells, promotes the development of MM with extramedullary disease.[37] 7.1%). All these data suggest that RAS pathway mutations play an important role in the development of EMD (**Table 3**).

Prognosis and Therapy of Patients with Emm (EMD). The prognosis of MM has very much improved with the new drugs and the immunological therapies but not at the same degree in all forms of myeloma, like the

EMM.[1,15,17,27] Considering that the old therapies have been abandoned, we will consider the late investigations, which include the new drug Bortezomib and its derivatives and immunotherapies. However, most of the studies are retrospective and report together different trials, various therapies, and patients at onset and at relapse. Furthermore, the classification of EMD follows different criteria, and there is not always a distinction between EM-E and EM-B in EMD. EMM form sometimes corresponds to EMD and other times to EM-E. Furthermore, the same pathology has been called by different names, and at present, EMD meaning is restricted to the soft tissues without any contact with bone marrow.

In any case, all the authors who make a distinction between paraskeletal forms/bone-associated EMD (EM-B) and soft/neurological tissues extramedullary forms (EM-E) find a worse prognosis in the EM-E forms either found at the onset of the diseases or at relapse.[11,13,15,17,27,38] Furthermore, the secondary forms have a very poor prognosis, less than 5 months (**Table 4**).[42]

Table 4. Therapy of New Diagnosis Patients: Outcome of MM versus EMD (EMM).

Author, Year, reference n°	Patients N°	Therapy	Risk factors	OS Months
Song, 2024, 27	NDMM MM=339 EM-B=33 EM-E=19	bortezomib + cyclophosphamide + dexamethasone and bortezomib + lenalidomide +	C-MYC EM-E	MM:60 pEM-E: 32 sEM-E:17
Moreau 2017, 38	NDMM MM:134 EM-E:10	Bortezomib-Lenalidomide-Desametazone	EM-E HR cytogenetics	DFS EM-E 47% EM-B 35% MM 54%
Jimenez-Segura, 2022, 39	NDMM= 1048 EM-B = 230 EM-E= 26	Proteasome-inhibit. +immunomodulator (PI+IMiD)	EM-E	MM: 45 EM-B: 44 EM-E: 20
Gao, 2022, 40	NDMM MM=226 EM-B 19 % EM-E 10.2%	Auto-HSCT could partly improve EMD patients' outcome as well MM.	EMD diagnosis, +calcemia, LDH. 1q21 amplification	MM 82 vs EMD 46 EM-B 51 vs EM-E 26
Zanwar, 2023, 42	EM-E =299 (at onset) (68%)second. (32%) de novo	PI plus IMiD ± a CD38 VDT-PACE like Either PI or IMiD-based combination (no differences in OS)	EM-E, LDH, ISS stage 3 Predictors: y. age, 1q duplex t(4;14)	EM-E Sec: 8 +37 De novo: 43 No EMD :85
Wang, 2023, 14	518 at onset EMD =121(24%) EM-B=91 EM-E=30	Bortezomib+Lenolamid Bortezomib-Lenolamid Autotransplant CAR T	EM-E Labelling Index	EM-E 26.5 no-EMD: 68.5 , p < 0.001; EM-B: 60.0 No sd,

Ta BCMA= B-cell ble 5 maturation antigen NDMM= New Diagnosis MM RRMM= Resistant Relapsing MM. EMD= Extramedullary Myeloma Disease EM-E=Extramedullary Disease, Extraosseous; pEM-E: primitive EM-E: sPM-E secondary sEM-E

At the onset of the disease, we have data from a few original articles.[27,38-42] All have found that the absence of EMD at diagnosis was an independent prognostic factor for a longer progression-free survival (PFS and OS). The difference in OS and PFS between patients with and without paraskeletal involvement was abolished by hematopoietic auto-transplant.[39,43]

Jimenez-Segura and coworkers have investigated a group of 1304 patients and observed that 19.6% of these patients at diagnosis had EMM: 17.6% EM-B and 1.9% EM-E. The only factor associated with EMM at relapse was the presence of EMM at diagnosis. In patients undergoing ASCT, only the presence of EM-E was associated with reduced OS compared to EM-B and MM; in patients not eligible for ASCT, the presence of EM-B or EM-E was associated with shorter OS.[39] Gao and coworkers explored 226 MM patients with or without EMD: 19% had EM-B and 10.2% EM-E; the OS for EMM and MM patients was 44 and 82 months,

respectively; the PFS 24 and 36 months, respectively.[40]

Goldman-Mazur et al. have explored the predictors of disease progression in 1557 MM patients following primary therapy and observed that short PFS (<2 years) was associated with high-risk cytogenetics, EMD, and plasma cell labeling index.[41]

Zanwar et al. retrospectively analyzed the outcomes of 204 patients with secondary EMD, and 95 with de novo EM-E; the median OS was 0.7 years for secondary EM-E and 3.6 years for de novo EM-E; the median PFS was 2.9 months for secondary EM-E and 12.9 months for de novo EM-E.[42] A multivariate analysis showed that age at diagnosis, 1q duplication, and t(4;14) at diagnosis of MM are independent predictors of the development of secondary EMM.[42] Wang et al. explored 518 MM patients of which 121 presented with EMD; patients with EM-E had the worst PFS and OS; in contrast, EM-B patients displayed PFS and OS comparable to those observed in MM.[14] ASCT significantly improved OS of

Table 5. Bispecific antibodies and CAR T-Cells Therapy of Resistant or Relapsing Multiple Myeloma MM versus Resistant or Relapsing EMD.

Author, Year, reference n°	Patients N°	Therapy	Risk factors	OS Months
Mateos, 2023, 49	RRMM 63 EM-E 27	teclistamab (tec) + talquetamab (tal)	EM-E	No EM-E CR: 34% EM-E 31%
Lesokhim, 2023, 50	123 patients without prior BCMA- therapy EMD= 45%	Erlanatamab	EM_E ISS 3	ORR % EMD 39 (31%): 63 NON EMD (69) 74
Hashmi 2023, 52	RRMM 211 EMD 95 (45%)	idecabtagene vicleucel (ide-cel)	EM-E; t(4;14) Ferritin; prior BCMA targ.ther. Bridging ther.	Data on OS are lacking
Zanwar, 2024, 51	RRMM 351, 84 (24%) EMD	decabtagene vicleuce (Ide-cel)	EMD	EMD: 14.8 No-EMD: 26.9
Qi, 2024, 54	RRMM EMD:31	anti-BCMA CAR T-cell	EM-E	EMD: 9.7
Dima, 2024, 56	RRMM 152 EMD (EM-E) 47	(BCMA) CAR T-cell	EM-E	EMD 12.2 vs 27.5 no EMD p = 0.00058

BCMA= B-cell maturation antigen. NDMM= New Diagnosis MM. RRMM= Resistant Relapsing MM. EMD= Extramedullary Myeloma Disease. EM-E=Extramedullary Disease, Extraosseous. pEM-E: primitive EM-E: sPM-E secondary sEM-E

EMD patients.[14] A prognostic model comprising LDH levels, circulating plasma cells, del(17p), and the type of EMD involvement was developed.[14]

Resistant Relapsing Myeloma Patients with and Without EMD Treated with Immunotherapy. Superiority of CAR T-Cell therapy and or B-specific antibodies vs traditional drugs in resistant relapsing Myeloma (RRMM) is an acquired datum.

EMD constitutes 25-45 % of RRMM submitted to immune therapy with B-specific Antibodies and/or CAR T-Cells (**Tables 4, 5**).[15,17,43-58]

B-specific Antibodies. In multiple myeloma (MM), bispecific T-cell engagers (BsAb) targeting B-cell maturation antigen (BCMA), G protein-coupled receptor, class C, group 5, member D (GPRC5D), and Fc receptor-like 5 (FcRL5) have already demonstrated remarkable clinical activity in triple-class refractory patients. However, responses to BsAb are not universal, and resistance often emerges while on therapy.[43]

We report the result of trials utilizing the 3 different B-specific antibodies, Taclistamab, directed against CD3 and BCMA (B-cell maturation antigen), Talquetamab against CD3 and GPRC5D (G-protein coupled receptor family C group 5 member D); Erlanatamab is, like Talquetamab directed against CD3 and BCMA, however it is a humanized antibody.

Teclistamab showed remarkable clinical activity in triple-class refractory patients in the multicenter phase I/II tMajesTEC-1 trial, including a total of 165 refractory MM patients; however, the ORR for EMM patients (17%) was 35%; significantly lower than for MM patients without EMD (63%) (**Figure 1**).[44,45]

In a polycentric study of German centers, 123 patients with RRMM, treated with Teclistamab, had an ORR of


Figure 1. RRMM Patients with and without EMD treated with b-specific antibody Teclistamab; Ref 44, Blood 2023

52,3% and a PFS of 8,7 months, the 43 patients (36%) with extramedullary disease had a significantly lower ORR (37%) and median PFS (2.1 months).[46]

Similarly, in a pooled analysis of outcomes of R/R patients with EMM, treated with a bispecific antibody Talquetamab, In the MonumenTAL-1 study, the ORR was significantly higher in the overall MM population than in patients with EMD (70-75% vs. 40-45%, respectively);[47] in the context of the LocoMMotion and MoMMent trials, a reduced PFS and OS compared to patients without EMM (PFS: 23 months vs 5.1 months; OS: 7.2 months vs 15.1 months, respectively) was observed.[47,48]

The first results from the RedirecTT-1 study with both the anti-BCMA-directed bispecific antibody Teclistamab (Tec) and the anti-GPRC5D-directed

bispecific antibody Talquetamab (Tal) evaluated the safety and efficacy in a group of 63 R/R MM patients, 43% with EMM: ORR was 84% among all evaluable patients and 73% in those with EMD; CR rate was 31% in all evaluable patients and 33% among those with EMD.[49] Importantly, at dose 2 of Tec/Tal, the ORR was 92% in all patients and 83% in those with EMD (**Table 5**).[49]

In spite of the limited efficacy of all available treatments for EMD patients, it is important to note that some new agents in ongoing evaluation in MM patients have shown high rates of response among patients with extramedullary disease. Erlanatamab, a humanized bispecific antibody, after the phase I MagnetisMM-1 study that provided preliminary encouraging safety and efficacy results on R/(RRMM patients, was explored in the registrational phase II MagnetisMM-3 study involving a total of 187 R/R MM patients.[50] 31.7% of the patients have extramedullary disease and the probability of maintaining the response at 15 months in these patients was 63.8% compared to 74.6% in the group of patients without EMD (**Table 5**).[50]

CAR-T. (**Table 5**)Idecabtagene vicleucel (Ide-Cel), a chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen (BCMA), has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes of Ide-Cel in patients with extramedullary disease (EMD) remain incompletely characterized. A multicenter study included patients with RRMM treated with ide-cel between May 2021 and April 2023 across 11 US academic institutions.[51] Visceral or soft tissue lesions non-contiguous from bone were classified as EMD. Time-to-event analyses were performed from the date of ide-cel infusion. Among 351 patients, 84 (24%) had EMD prior to infusion. The median follow-up from ide-cel infusion was 18.2 months (95% CI: 17-19.3). The day 90 overall response rates (ORR) were 52% vs. 82% for the EMD and non-EMD cohorts, respectively (p < 0.001). The median progression-free survival (PFS) was 5.3 months (95% CI: 4.1–6.9) for the EMD cohort vs. 11.1 months (95% CI: 9.2–12.6; p < 0.0001) for the non-EMD cohort. In a multivariable analysis, EMD was an independent predictor of inferior PFS [hazard ratio 1.5 (1.1–2.2), p = 0.02]. The median overall survival was 14.8 months [95% CI: 9-Not reached (NR)] vs. 26.9 months (26.3 vs. NR, p = 0.006) for the EMD and non-EMD cohorts, respectively. In another study,[52] 211 RRMM patients that received Ide-Cel, 43 (20%) of them had a progressive event ≤3 months of infusion; of 95 EMD (45%), 26 (27%) had a progressive event ≤3 months from infusion, while of the 116 non-EMD, only 17 (15%) progressed.[52] Therefore, extramedullary disease represents an independent predictor of inferior day 90 ORR and PFS among patients treated with Ide-Cel.

In a Chinese study[53] including 69 RRMM patients treated with combined anti-BCMA and anti-CD19 CAR T-cell, the 15 EMD (24%), with extramedullary disease, had significantly poorer PFS (median of 8.3 months [95% CI, 0.2 to 16.4] v21.4 months [95% CI, 9.2 to 33.5]) and OS (median of 12.3 months v not reached) than patients without extramedullary disease. The same group confirmed these data in a prospective study on thirty-one EMD patients.[54] Discrepancies in treatment response were noted between medullary and extramedullary diseases, with EMD exhibiting suboptimal and delayed response, as well as shortened response duration. The overall response occurred in 90.3% of medullary disease and 64.5% of EMD (p = .031) With a median follow-up of 25.3 months, the median progression-free and overall survival were 5.0 and 9.7 months, respectively. progression within 6 months post-infusion is strongly associated with an increased risk of death (HR = 4.58; p = .029). Compared with non-EMD patients, patients with EMD experienced EMD progression, primarily in the form of BCMA+ progression, with inferior survival outcomes.

Analog results were obtained in 134 patients with RRMM treated with CAR-T cell therapy, utilizing mostly ciltacabtagene autoleucel or idacabtagene vicleucel (Cita.cel); 25.5% of patients were at baseline EMM-E, and the remaining were classified as EMM-B (18.7%) or MM (56%).[55] Compared to MM patients, EMM-B patients had similar PFS and OS, while EMM-E patients displayed shorter PFS and OS and ORR lower compared to EMM-B or MM.[55]

Very recently in a retrospective analysis involving 152 refractory/relapsed MM patients, have been reported the results obtained with the treatment of a commercial CAR-T cells: the patients with EMM (31%) had an inferior overall survival rate (58% vs. 96%), mPFS (5.1 months vs 12.4 months) and mOS (12.2 vs 27.5 months) compared to 69% non-EMM group.[56] Importantly, patients with paramedullary disease had mPFS and mOS comparable to those observed in patients with bone marrow-only disease.[56] Similar results have been reported in 2 standard-of-care settings, one American recently reported in Blood and presented at ASH Congress 2024.[57] and the other French (**Figure 2**).[58] It is important to signal the high rate of ORR present also in the high risk, like HR cytogenetics and extramedullary localization. However, these HR forms relapse frequently and have reduced PFS and OS. A tentative to explain the reduced efficacy in patients with EMD has been reported in oral communication of the ASH Congress 2024.[59] This presentation reports the biodistribution of cilta-cel, labelled with Cu-64 SPION, using novel nanoparticle-based tracking technology, combined with immunological correlative studies on blood, bone marrow, and plasmacytoma biopsies, in

Figure 2. Progression Free Survival of RRMM patients with and without in EMD treated with CAR-T in two different standard-of-care settings [A: decabtagene vicleucel (ide-cel); B: Ciltacabtagene autoleucel (cilta-cel) Ref: A:58, Br J Haematol 2024 and B:57, Blood. 2024]

order to elucidate the biology of resistance in extramedullary myeloma and identify opportunities for novel interventions to improve outcomes. The distribution of radioisotope at 12 hrs was 53% to the liver, 16% to the spleen, and 3% to the bone marrow. Specific uptake at the soft tissue plasmacytomas was not observed over the first 4 days. Analysis of longer-term tracking on MRI by the SPION component of the nanoparticles and correlative immunological studies on blood, marrow, and plasmacytoma biopsies is ongoing.

Similar or better results are possible with anti-GPRC5D CAR T-cell therapy. However, the number of patients treated is low; only 33 11 of them showed extramedullary localization and had an ORR identical (91%) to the patients without EMD, but there are no data about PFS or OS.[60] Thus, the G protein-coupled receptor, class C group 5 member D (GPRC5D), a membrane antigen highly expressed on malignant plasmacytes, is a promising target for MM (**Table 5**).

Vegivinti and coworkers have performed a systematic review and meta-analysis of all the studies carried out using bispecific antibodies or CAR-T cells for the treatment of MM patients with either extramedullary disease or with high-risk features and observed that the responses to CAR-T cell therapy were superior for both these types of patients to CAR-T cell therapy than to bispecific antibodies.[61]

However, two very recent studies suggest that the patients resistant or relapsing after CAR T-cell can respond to b-specific antibodies.[62,63] Efficacy and safety of teclistamab were tested in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies; eligible patients were triple-class exposed, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and must have also been previously exposed to an anti-BCMA treatment, either CAR-T therapy or an ADC; they had progressive, measurable disease at

screening. In forty eligible patients, the ORR was 52.5% (95% CI, 36.168.5). Rates of very good partial response (VGPR) or better and CR or better were 47.5% (95% CI, 31.5-63.9) and 30.0% (95% CI, 16.6-46.5), respectively. Efficacy was similar in patients with different prior treatments. The 12 EMD patients (30%) had a similar ORR (58.3%). The PFR was not reported.[62]

Furthermore, Bispecific antibodies targeting BCMA or GPRC5D were highly effective in relapsed myeloma after CAR T-cell therapy.[63] 139 patients in relapse after (n = 130 ide-cel, n = 9 cilta-cel), received talquetamab (n = 28), teclistamab (n = 37), combinations of immunomodulating drugs (IMiDs), proteasome inhibitors (PIs) or CD38 monoclonal antibodies (n = 43), and others (n = 31). Of them 53% had the extramedullary disease (EMD). Overall response and complete response upon salvage therapies were 79% and 39% for talquetamab, 64% and 32% for teclistamab, 30% and 0% for IMiDs/PIs/CD38, and 26% and 3% for others (P < 0.001). The median OS of all patients was 9 months (95% CI, 4–14 months). Half of the total cohort (53%) showed relapse with EMD, and extramedullary relapse was significantly associated with dismal post-relapse outcome (P= 0.005), with a median OS of 5 months (95% CI, 3–7 months) versus median OS not reached for patients with non-EMD relapse.

Conclusions. At present, true extramedullary myeloma (EMD) has localization in the soft tissues, which results from hematogenic spread; it represents an aggressive form of MM, which can be found at the time of MM diagnosis or at relapse. True EMD is restricted to plasmacytomas that arise from hematogenous spread and have no contact with bony structures. The hematological spread of plasma cells is a very important factor in prognosis; more and more investigations show that the level of circulant plasma tumor cells is a very important risk factor in all forms of MM and should be added to the

other factors to determine the ISS. The Paraskeletal plasmacytoma, although localized in soft tissue plasmacytomas, is due to direct growth from skeletal tumors following cortical bone disruption and has a prognosis similar to that of the classical form of MM. The new therapies have improved the prognosis only slightly, and daratumumab, an anti-CD 38 antibody, has limited efficacy in multiple myeloma with extramedullary disease[64] due to decreased CD38 expression on EMM plasma cells.[65]

CAR T cells and bispecific antibodies have therapeutic activity in RRMM but less efficacy in EMD. The ORR is not always reduced, but the long-term survival benefits may be limited. The EMD-specific microenvironment potentially impacts treatment. Therefore, the EMD remains classified as ultrahigh-risk myeloma at bad prognosis.

Further efforts are needed to extend EMD remission and improve long-term outcomes.

References:

1. Rees MJ, D'Agostino M, Leypoldt LB, Kumar S, Weisel KC, Gay F. Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433520.
https://doi.org/10.1200/EDBK_433520
PMid:38772002

2. Sanoja-Flores L, Flores-Montero J, Garcés JJ, Paiva B, Garcia-Mateo A, Garcia-Sanchez A, Corral-Mateos A, Burgos L, Blanco E, Hernandez-Martin J, et al. Next generation flow cytometry for minimally invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J 2018; 8: 117.
https://doi.org/10.1038/s41408-018-0153-9
PMid:30455467 PMCid:PMC6242818

3. Gundesen MT, Lund T, Moeller HEH. Plasma cell leukemia: definition, presentation and treatment. Curr Oncol Rep 2019; 21: 8.
https://doi.org/10.1007/s11912-019-0754-x
PMid:30689121 PMCid:PMC6349791

4. Terpos E, Kostopoulos IV, Papanota AM, Papadhimitriou K, Malandrakis P, Michell P, Ntanasis-Stathopoulos I, Fotiou D, Metousis A, Kanellas N, et al. Next generation flow cytometry provides a standardized, highly sensitive and informative method for the analysis of circulating plasma cells in newly diagnosed multiple myeloma: a single center study of 182 patients. Blood 2019; 134 (suppl.1): 4338.
https://doi.org/10.1182/blood-2019-127989

5. Garcés JJ, Cedena MT, Puig N, Burgos L, Perez JJ, Cordon L, Flores-Montero J, Sanoja- Flores L, Calasanz MJ, Ortiol A, et al. Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J Clin Oncol 2022; 40: 3151-3161.
https://doi.org/10.1200/JCO.21.01365
PMid:35666958

6. Bertamini L, Oliva S, Rota-Scalabrini D, Paris L, Moré S, Corradini P, Ledda A, Gentile M, De Sabbata G, Pietrantuono G, Pascarella A, et al. High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol 2022; 40: 3120-3131.
https://doi.org/10.1200/JCO.21.01393
PMid:35666982

7. Kostopoulos IV, Ntanatis-Stathopoulos I, Rousakis P, Eleutherakis-Papaiakovou E, Panteli C, Malandrakis P, Angelis N, Kanellias N, Orologas-Stavrou N, Papanota A, et al. Circulating plasma cells in newly diagnosed multiple myeloma: prognostic and more. J Clin Oncol 2023; 41: 708-710.
https://doi.org/10.1200/JCO.22.01606
PMid:36179274

8. Kostopoulos IV, Ntanatis-Stathopoulos I, Rousakis P, Eleutherakis-Papaiakovou E, Panteli C, Malandrakis P, Angelis N, Kanellias N, Dimitrakopoulou G, Theodorakakou F, et al. Low levels of circulating tumor cells correlate with favorable clinical outcome and unique biological features in newly diagnosed multiple myeloma patients. Blood 2023; 142 (suppl.1): 880.
https://doi.org/10.1182/blood-2023-186259

9. Jelinek T, Bezdekova R, Zihala D, Seccikova T, Sithara AA, Pospisilova L, Sevcikova S, Pothakova P, Stork M, Knecktova Z, et al. More than 2% of circulating tumor plasma cell leukemia-like multiple myeloma. J Clin Oncol 2023 41(7):1383-1392.
https://doi.org/10.1200/JCO.22.01226
PMid:36315921 PMCid:PMC9995102

10. Chu B, Wang Y, Shi L, Sun K, Bao L. Combination of circulating plasma cells enhances the efficacy of R2-ISS stage system for risk classification

of newly diagnosed multiple myeloma: a single-center real-world study. Blood 2023; 142 (suppl.1): 4740.
https://doi.org/10.1182/blood-2023-181006

11. Ikeda D, Tearo T, Oura M, Uehara A, Tabata R, Narita K, Takeuchi M, Machida Y, Matsue K, et al. A prognostic model integrating circulating clonal plasma cells into R-ISS and PET-CT based tumor burden in transplant-ineligible multiple myeloma. Blood 2023; 142 (suppl.1): 1972.
https://doi.org/10.1182/blood-2023-189137

12. Fernandez de Larrea C, Kyle R, Rosiñol L, et al: Primary plasma cell leukemia: Consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J 11:192, 2021
https://doi.org/10.1038/s41408-021-00587-0
PMid:34857730 PMCid:PMC8640034

13. Geng S, Wang J, Zhang X, Zhang JJ, Wu F, Pang Y, Zhong Y, Wang J, Wang W, Liu X, Huang Y, Jing H. Single-cell RNA sequencing reveals chemokine self-feeding of myeloma cells promotes extramedullary metastasis. FEBS Lett. 2020 Feb;594(3):452-465.
https://doi.org/10.1002/1873-3468.13623
PMid:31561267

14. Wang J, Shen N, Shen X, Zhang R, Jin Y, Li J, Chen L. Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease. Ann Med. 2023;55(2):2281657.
https://doi.org/10.1080/07853890.2023.2281657
PMid:38086395 PMCid:PMC10880573

15. Bladé J, Beksoc M, Caers J, Jurcryszyn A, von Lilienfold-Toal M, Moreau P, Rasche L, Rosinol L, Umani SZ, Zamagni E, Richardson P. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 2022; 12: 45.
https://doi.org/10.1038/s41408-022-00643-3
PMid:35314675 PMCid:PMC8938478

16. Bladé J, Fernández de Larrea C, Rosiñol L. Extramedullary disease in multiple myeloma in the era of novel agents. Br J Haematol. 2015 Jun;169(6):763-5.
https://doi.org/10.1111/bjh.13384
PMid:25825255

17. Bansal R, Rakshit S, Kumar S. Extramedullary disease in multiple myeloma. Blood Cancer J 2021; 11: 161
https://doi.org/10.1038/s41408-021-00527-y
PMid:34588423 PMCid:PMC8481260

18. Hirao M, Yamazaki K, Watanabe K, Mukai K, Hirose S, Osada M, Tsukada Y, Kunieda H, Denda R, Kikuchi T, Sugimori H, Okamoto S, Hattori Y. Negative E-cadherin expression on bone marrow myeloma cell membranes is associated with extramedullary disease. F1000Res. 2022 Feb 28;11:245.
https://doi.org/10.12688/f1000research.109551.2
PMid:35646332 PMCid:PMC9117942

19. Cerchione C, Usmani SZ, Stewart AK, Kaiser M, Rasche L, Kortüm M, Mateos MV, Spencer A, Sonneveld P, Anderson KC. Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. Front Oncol. 2022 Feb 8;12:820768.
https://doi.org/10.3389/fonc.2022.820768
PMid:35211412 PMCid:PMC8861274

20. Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, Paba-Prada C, Warren D, Maglio ME, Schlossman R, Munshi NC, Raje N, Weller E, Anderson KC, Mitsiades CS, Richardson PG. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun;169(6):843-50.

https://doi.org/10.1111/bjh.13382
PMid:26032514

21. Rasche L, Bernard C, Topp MS, Kapp M, Duell J, Wesemeier C, Haralambieva E, Maeder U, Einsele H, Kno S. Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol 2012; 91: 1031-1037
https://doi.org/10.1007/s00277-012-1414-5
PMid:22286070

22. Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Heidtmann HH, Vettorazzi E, Dierlamm J, Bokemeyer C, Schilling G. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013 Apr;161(1):87-94.
https://doi.org/10.1111/bjh.12223
PMid:23368088

23. Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, Jelinek T, Pour L, Pou L, Adam Z, et al. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol 2016; 97: 93-100.
https://doi.org/10.1111/ejh.12688
PMid:26432667

24. Qu X, Chen L, Qiu H, Lu H, Wu H, Qiu H, Liu P, Guo R, Li J. Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents' resistance. Biomed Res Int 2015; 2015: 787809.
https://doi.org/10.1155/2015/787809
PMid:25984534 PMCid:PMC4423005

25. Kriegova E, Fillerova R, Minarik J, Savara J, Manakova J, Petrackova A, Dihel M, Balcarkova J, Krhovska P, Pika T, et al. Wole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. Sci Rep 2021; 11: 14671.
https://doi.org/10.1038/s41598-021-93835-z
PMid:34282158 PMCid:PMC8289962

26. Xia Y, Shi Y, Zhang J, Zhu Y, Guo R, Zhang R, Shi Q, Li J, Chen L. Characteristics, and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma. Chinese Med J 2022; 135: 2500-2502.
https://doi.org/10.1097/CM9.0000000000002351
PMid:36583869 PMCid:PMC9945484

27. Song Y, Du J, Jin X, Li H, Jia C, Liu Y, Li K, Zhou, Zhuang J. MYC translocation is a valuable marker for the development and relapse of extramedullary disease in multiple myeloma. Eur J Haematol 2024; 113(6):824-832.
https://doi.org/10.1111/ejh.14296
PMid:39191670

28. Gao S, Dong F, Yang P, Chen Y, Wang Y, Wang J, Shi Y, Jing H. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study. Ann Hematol. 2024;103(6):1979-1987.
https://doi.org/10.1007/s00277-023-05588-6
PMid:38206369

29. Deng S, Xu Y, An G, Sui W, Zou D, Zhao Y, Qio J, Li F, Hao M, Qiu L. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center of 834 cases. Clin Lymphoma Myeloma Leuk 2015; 15: 286-291
https://doi.org/10.1016/j.clml.2014.12.013
PMid:25640025

30. Andrulis M, Lehners N, Capper D, Penzer R, Heining C, Huellein J, Zenz T, von Deimiling A, Schirmacher P, Ho AD, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 2013; 3: 862-869.
https://doi.org/10.1158/2159-8290.CD-13-0014
PMid:23612012

31. De Haart SJ, Willems SM, Mutis T, Koudijs MJ, van Blokland MT, Lokhorst HM, de Weger RA, Minnema MC. Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses. Blood Cancer J 2016; 6: e426.
https://doi.org/10.1038/bcj.2016.35
PMid:27206246 PMCid:PMC4916304

32. Liu Y, Jelloul F, Zhang Y, Bhavsar T, Ho C, Rac M, Lewis NE, Cimera R, Baik J, Sigler A, et al. Genetic basis of extramedullary plasmablastic transformation of multiple myeloma. Am J Surg Pathol 2020; 44: 838-848.
https://doi.org/10.1097/PAS.0000000000001459
PMid:32118627 PMCid:PMC7225029

33. Nakamoto-Matsubara R, Nardi V, Panaroni C, Fulzele K, Mori T, Verma R, Yee AJ, Branagan AR, O'Donnell E, Raje NS, et al. Molecular features and clinical outcomes of extramedullary plasmacytomas. Blood 2021; 138(suppl.1): 398-399
https://doi.org/10.1182/blood-2021-152784

34. Saladarriaga MM, Jayabalan D, Sowa A, Monge J, Rosenbaum C, Pearse R, Nievisky R, Patel S, Bustoros M. Genomic landscape of multiple myeloma with extramedullary disease: results from a large patient database. J Clin Oncol 2023; 41(suppl. 16): 8058
https://doi.org/10.1200/JCO.2023.41.16_suppl.8058

35. Jelinek T, Zihala D, Sevcikova T, Anilkumar Sithara A, Kapustova V, Sahinbegovic H, Venglar O, Muronova L, Broskevicova L, Nenarokov S, Bilek D, Popkova T, Plonkova H, Vrana J, Zidlik V, Hurnik P, Havel M, Hrdinka M, Chyra Z, Stracquadanio G, Simicek M, Hajek R. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. 2024 Jun;38(6):1323-1333.
https://doi.org/10.1038/s41375-024-02206-w
PMid:38493239 PMCid:PMC11147761

36. Rizq O, Mimura N, Oshima M, Momose S, Takayama N, Itokawa N, Koide S, Shibamiya A, Miyamoto-Nagal Y, Rizk M, et al. UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease. Leukemia 2023; 37: 1895-1907
https://doi.org/10.1038/s41375-023-01928-7
PMid:37198323 PMCid:PMC10457198

37. Long X, Xu Q, Lou Y, Li C, Gu J, Cai H, Wang D, Xu J, Li T, Xhou X, Xiao M, et al. The utility of non-invasive liquid biopsy for mutational analysis and minimal residual disease assessment in extramedullary multiple myeloma. Br J Haematol 2020; 189: e45-e48.
https://doi.org/10.1111/bjh.16440
PMid:32191818

38. Moreau P, Göker H, Demiroğlu H, Aksu S, Sayınalp N, Haznedaroğlu IC, et al. Prospective evaluation of magnetic resonance imaging and [18F]fluorodeox- yglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35:2911-8.
https://doi.org/10.1200/JCO.2017.72.2975
PMid:28686535 PMCid:PMC5578392

39. Jimenez-Segura R, Rosinol L, Cibeira MT, Fernandez de Larrea C, Tovar N, Rodriguez- Lobato LG, Bladé E, Moreno DF, Oliver-Caldés A, Bladé J. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at firsty relapse: 50-years of experience from an academic institution. Blood Cancer J 2022; 12: 135.
https://doi.org/10.1038/s41408-022-00730-5
PMid:36114167 PMCid:PMC9481598

40. Gao S, Li Q, Dong F, Yang P, Chen Y, Wang J; Wang Y, Jing H. Clinical characteristics, and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: a retrospective study. Leuk Res 2022; 115: 106793
https://doi.org/10.1016/j.leukres.2022.106793
PMid:35248783

41. Goldman-Mazur S, Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA; Buadi FK, Hayman SR, Dingli D, et al. Predictors and impact of timing of disease progression following primary therapy in multiple myeloma. Clin Lymphoma Myeloma Leuk 2023; 27: S2152-2160

42. Zanwar S, Ho M, Lin Y, et al: Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol 98: 1540-1549, 2023
https://doi.org/10.1002/ajh.27023
PMid:37421603

43. Lee H, Neri P, Bahlis NJ. Current use of bispecific antibodies to treat multiple myeloma. 2023; Hematology, ASH Education Program: 332-339.
https://doi.org/10.1182/hematology.2023000433
PMid:38066842 PMCid:PMC10727080

44. Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel J, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022 Aug 11;387(6):495-505.
https://doi.org/10.1056/NEJMoa2203478
PMid:35661166 PMCid:PMC10587778

45. Moreau P, Mateos MV, Goldschmidt H, Garcia EG, Besemer B, Perez MSG, Mohty M, Lindsey-Hill J, Kirkpatrick S, Delforge M, et al. Outcomes of patients with extramedullary disease in triple-class exposed relapsed/refractory multiple myeloma from the LocoMMotion + MoMMent studies. Blood 2023; 142 (suppl.1): 4698.

https://doi.org/10.1182/blood-2023-181235

46. Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, Einsele H, Faltin J, Frenking J, Gezer D, Goldman-Mazur S, Hänel M, Hoegner M, Kortuem KM, Krönke J, Kull M, Leitner T, Mann C, Mecklenbrauck R, Merz M, Morgner A, Nogai A, Raab MS, Teipel R, Wäsch R, Rasche L. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024 Feb;38(2):365-371. https://doi.org/10.1038/s41375-024-02154-5 PMid:38245601 PMCid:PMC10844072

47. Chari A, Minnema MC, Berdeja BC, Oriol A, van de Donk N, Rodriguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 2022; 387: 2232-2244.. https://doi.org/10.1056/NEJMoa2204591 PMid:36507686

48. Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez-Lopez J, Rodríguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos MV. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. Adv Ther. 2024 Apr;41(4):1576-1593. https://doi.org/10.1007/s12325-024-02797-x PMid:38402374 PMCid:PMC10960754

49. Mateos MV 1, Morillo D 2, Gatt M3, Sebag M 4, Kim K5, Min CK 6 et Al. 1First results fron RedirecTT-1 study with teclistamab (tec) + taquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Hemasphere 2023 Aug 8;7(Suppl): e15362d7. https://doi.org/10.1097/01.HS9.0000967672.15362.d7 PMCid:PMC10428427

50. Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Prince HM, Niesvizky R, Rodriguez- Otero P, Martinez-Lopez J, Kohne G, Touzeau C, et al. Erlanatamab in relapsed or refractory multiple myeloma: phase 2 ManetisMM-3 trial results. Nat Med 2023; 29: 2259-2267 https://doi.org/10.1038/s41591-023-02528-9 PMid:37582952 PMCid:PMC10504075

51. Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD Jr, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024 Jun 6;17(1):42. https://doi.org/10.1186/s13045-024-01555-4 PMid:38845015 PMCid:PMC11157748

52. Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avita G, Sidana S, Shune L, Sborov DW, Davis J, et al. Factors associated with refractoriness of early progression after idecabtagene vivleucel in patients with relapsed/refractory multiple myeloma: US myeloma immunotherapy consortium real world experience. Haematologica 2024; 109(5):1514-1524. https://doi.org/10.3324/haematol.2023.283888

53. Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, Jin L, Xia J, Ma S, Liu Y, Li H, Pan B, Chen W, Fei X, Wang C, Xie X, Yu L, Wang G, Li H, Jing G, Cheng H, Zhu F, Sun H, Sang W, Li D, Li Z, Zheng J, Xu K. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin Oncol. 2022 Jul 10;40(20):2246-2256. https://doi.org/10.1200/JCO.21.01676 PMid:35333600

54. Qi Y, Li H, Qi K, Zhu F, Cheng H, Chen W, Yan Z, Li D, Sang W, Fei X, Gu W, Miao Y, Huang H, Wang Y, Qiu T, Qiao J, Pan B, Shi M, Wang G, Li Z, Zheng J, Xu K, Cao J. Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy. Am J Hematol. 2024 Dec;99(12):2286-2295. https://doi.org/10.1002/ajh.27469 PMid:39194355

55. Pan D, Mouhieddine TH, Fu W, Moshier E, Parekh S, Jagannathan S, Rossi AC, Richter J, Rodriguez C, Sanchez LJ, et al. Outcomes after CAR T cells in multiple myeloma patients with extramedullary and paramedullary disease. Blood 2023; 142(suppl. 1): 652 https://doi.org/10.1182/blood-2023-177749

56. Dima D, Abdallah AO, Davis JA, Awada H, Goel U, Rashid A, Dejarnette S, Anwer F, Shune L, Raza S, et al. Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple

myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy. Blood Cancer J 2024; 14: 90. https://doi.org/10.1038/s41408-024-01068-w PMid:38821914 PMCid:PMC11143360

57. Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri CJ, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo RD, Nadeem O, Mann H, Kalariya N, Hovanky V, DeAvila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr MM, Htut M, McGuirk JP, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. Blood. 2024 Oct 4: blood. 2024025945. https://doi.org/10.1182/blood.2024025945 PMid:39365257

58. Ferment B, Lambert J, Caillot D, Lafon I, Karlin L, Lazareth A, Touzeau C, Leleu X, Moya N, Harel S, Perrot A, Bories P, Vincent L, Lamure S, Mohty M, Malard F, Manier S, Yakoub-Agha I, Schiano De Colella JM, Brisou G, Talbot A, Decaux O, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Moreau P, Arnulf B; Intergroupe Francophone du Myélome. French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry. Br J Haematol. 2024 Sep;205(3):990-998. https://doi.org/10.1111/bjh.19505 PMid:38747092

59. Dowling, M. R., Scott, H. W., Connor, T. L., Kelly, H., Lee, I. Y., Domingues, M., ... & Harrison, S. J. (2024). CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease-an In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI. Blood, 144, 1029. https://doi.org/10.1182/blood-2024-210017

60. Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, Cao J, Li D, Cheng H, Sang W, et al. Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol 2023; 41: 2583-2593 https://doi.org/10.1200/JCO.22.01824 PMid:36881785 PMCid:PMC10414745

61. Vegiviniti CT, Santhi J, Liu L, Keesari PR, Thakur R, Hammami MB, Kapu V, Pericherla S, Gopireddy MM, Poojary N, et al. Efficacy of bispecific antibodies cs CAR-T in the treatment of extramedullary disease and high-risk cytogenetics in relapsed multiple myeloma: a systematic review and meta-analysis. Blood 2023; 142 (suppl.1): 1994 https://doi.org/10.1182/blood-2023-190019

62. Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, Cavo M, Martinez Chamorro C, Nooka AK, Martin TG, Karlin L, Leleu X, Bahlis NJ, Besemer B, Pei L, Stein S, Wang Lin SX, Trancucci D, Verona RI, Girgis S, Miao X, Uhlar CM, Chastain K, Garfall AL. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024 Dec 5;144(23):2375-2388. https://doi.org/10.1182/blood.2023023616 PMid:39172760

63. Merz M, Dima D, Hashmi H, Ahmed N, Stölzel F, Holderried TAW, Fenk R, Müller F, Tovar N, Oliver-Cáldes A, Rathje K, Davis JA, Fandrei D, Vucinic V, Kharboutli S, Baermann BN, Ayuk F, Platzbecker U, Albici AM, Schub N, Schmitz F, Shune L, Khouri J, Anwer F, Raza S, McGuirk J, Mahmoudjafari Z, Green K, Khandanpour C, Teichert M, Jeker B, Hoffmann M, Kröger N, von Tresckow B, de Larrea CF, Pabst T, Abdallah AO, Gagelmann N. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. Blood Cancer J. 2024 Dec 5;14(1):214. https://doi.org/10.1038/s41408-024-01197-2 PMid:39632797 PMCid:PMC11618392

64. Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, Capkova L, Rihova L, Bezdekova R, Sevcikova S, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia 2022; 36: 288-291 https://doi.org/10.1038/s41375-021-01343-w PMid:34247197

65. Notarfranchi L, Accardi F, Mancini C, Martella E, Bonomini S, Segreto R, Vescovini R, Dalla Palma AB, Sammarelli G, Todaro G, et al. CD38 expression by plasma cells in extramedullary multiple myeloma. Haematologica 2024; 109(4):1297-1300. https://doi.org/10.3324/haematol.2023.284169 PMid:37941401